中文

News Center

Blockbuster | Up to 75% Reduction in Triglycerides, Up to 67% Reduction in Liver Fat: Doer Bio's DR10624 Phase 2 Clinical Results Shine in Opening Session at AHA 2025

2025/11/11

Read more

Preview | To Kick Off the Conference!Huadong Medicine’s Subsidiary Doer Bio's DR10624 Phase 2 Results for Severe Hypertriglyceridemia Selected as AHA 2025 Late-Breaker and Featured as Opening Presentation

2025/09/16

Read more

Doer Biologics Completes First Patient Dosing in Phase II Clinical Trial of DR10624 for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) / Metabolic Dysfunction-Associated Steatohepatitis (MASH)

2025/04/22

Read more

Doer Biologics Announced Completes Enrollment of the Phase 2 Clinical Study of DR10624, reported by mainstream media

2025/03/12

Read more

Doer Biologics Completes Patient Enrollment in Phase II Clinical Study of DR10624 for Severe Hypertriglyceridemia

2025/03/10

Read more

Doer Biologics Announced First Patient Dosed in Phase 2 Study of DR10624, reported by mainstream media

2024/10/09

Read more

World's First Triple Agonist DR10624 Completes Full Enrollment in Phase 1b/2a Clinical Trial for Obesity with Hypertriglyceridemia

2024/07/09

Read more

Zhejiang Doer Biologics Announces License Agreement with BioNTech

2023/07/11

Read more

Many mainstream media reported the collaboration between Zhejiang Doer Biologics and MSD

2022/12/19

Read more

Reported by PR Newswire published

2022/12/17

Read more